Published in final edited form as:

Adv Synth Catal. 2008 December 18; 350(18): 2885–2891.

An Enantioselective Synthesis of the ABD Tricycle for (–)-Phomactin A Featuring Rawal's Asymmetric Diels-Alder Cycloaddition

Ling-Feng You, Richard P. Hsung, Aaron A. Bedermann, Aleksey V. Kurdyumov, Yu Tang, Grant S. Buchanan, and Kevin P. Cole

Division of Pharmaceutical Sciences and Department of Chemistry, Rennebohm Hall, 777 Highland Avenue, University of Wisconsin, Madison, WI 53705, rhsung@wisc.edu and cole_kevin_p_phd@lilly.com

Abstract

An enantioselective synthesis of the ABD-ring of (–)-phomactin A is described here. The sequence features Rawal's asymmetric Diels-Alder cycloaddition. The overall length is significantly reduced from our previous attempt.

Keywords

Rawal's 1-amino-3-siloxy-1,3-butadiene; asymmetric Diels-Alder cycloaddition; Cr(III)-salen catalyst; intramolecular *oxa*-[3 + 3] annulation; and phomactin A

We have been pursuing the total synthesis of phomactin A, a biologically interesting and structurally unique natural product from the culture filtrate of a parasitic fungus *Phoma* sp. [SANK 11486] found on the shell of *Chinoecetes opilio* off the coast of Fukui prefecture in Japan.^{1–3} In the last 15 years, phomactin A and its other family members have attracted a number of impressive synthetic efforts^{4, 5} including Yamada's synthesis of (+)-phomactin D,⁶ total syntheses of (±)- and (+)-phomactin A by Pattenden⁷ and Halcomb,⁸ respectively, and most recently, Wulff's total synthesis of (±)-phomactin B.⁹ We¹⁰ disclosed our synthetic approach to (±)-phomactin A potentially through ABD tricycle **1**,¹¹ which can be accessed from an intramolecular *oxa*-[3 + 3] annulation of vinyl iminium salt **2**.^{12–14}

However, our total synthesis efforts have been seriously compromised by the fact that the annulation precursor **2** required 22 steps from 2-methyl-cyclohexanone, adopting a route not amenable for asymmetric total synthesis. Therefore, we have been exploring a conceptually different strategy. Specifically, by constructing the A-ring from a Diels-Alder cycloaddition instead of buying from 2-methyl-cyclohexanone, we hope to establish a much shorter and asymmetric synthesis of **1**. We report herein an enantioselective synthesis ABD-tricycle for (–)-phomactin A featuring Rawal's asymmetric Diels-Alder cycloaddition.

Our initial efforts quickly identified that Diels-Alder cycloaddition of tiglic aldehyde with Danishefsky's diene proceeded only at high temperatures [Scheme 2]. After acidic workup, this cycloaddition afforded, with variable yields, a complex mixture of products **3–5** including *para*-hydroxy-acetophenone **5**,¹⁵ likely derived from dimerization of the diene. On the other hand, cycloaddition with Rawal's diene^{16–20} did occur with remarkable ease. Although the

reaction was slow at $-10\text{ }^{\circ}\text{C}$ [ice/acetone], at 0.22 mol scale, it was complete within 20 h at $50\text{ }^{\circ}\text{C}$ in THF to afford the desired cycloadduct ($\pm$)-**6** in high yields as a single *endo* isomer.

It is noteworthy that the better reactivity towards tiglic aldehyde is likely a consequence of the dimethylamino group possessing stronger donating ability into the diene [significantly raising its HOMO level] relative to Danishefsky's diene.¹⁸ This key *endo*-selective cycloaddition sets up a majority of the stereochemistry in the A-ring, and provides extensive oxygenation for subsequent transformations. However, attempts to append a tethering fragment through nucleophilic addition to the aldehydic motif in ($\pm$)-**6** were not fruitful, and ($\pm$)-**6** was rather unstable to chromatography, and underwent clean elimination to give the enone under acidic conditions. With the knowledge of Halcomb's success in adopting Suzuki-Miyaura coupling,⁸ we proceeded to olefinate the aldehyde in ($\pm$)-**6**, and after hydrolysis, enone ($\pm$)-**7** was attained in 72% yield [Scheme 2]. A nucleophilic epoxidation and ketone protection gave vinyl epoxy acetal ($\pm$)-**8**, which was used for investigating the Suzuki-Miyaura coupling [*vide infra*].

We then turned our attention to pursuing an asymmetric Diels-Alder cycloadditions of tiglic aldehyde with the Rawal's carbamate diene **9**^{18–22} [Scheme 3]. Screening Corey's oxazaborolidine catalyst **12**²¹ only led to 1,4-addition and 1,2-addition products **16a** and **16b**.²³ Rawal¹⁹ had reported a related cycloaddition of tiglic aldehyde that gave 62% yield with 93% *ee* when using Jacobsen's Cr(III)-salen catalyst²⁴ [see **13** with SbF_6 as counter anion]. However, our attempts using diene **9** again resulted **16a** and **16b** with the best yield for the desired cycloadduct **10** being 36%. The use of Co(III)-salen catalyst **14** was also not useful and gave products related to 1,4-addition and 1,2-addition.²³ Ultimately, we were able to obtain **10** in 78% yield with *ee* up to 90% by using the (*R,R*)-Cr(III)-salen catalyst **15** with BF_4 as counter anion. The *ee* was determined by making the (*S*)-naproxen ester **11** [not crystalline and so no X-ray structure could be attained].

With optically enriched cycloadduct **10** in hand, we had trouble transforming it into enone ($\pm$)-**7**. As shown in Scheme 4, unlike that of **6**, Wittig olefination of **10** was <10% yield. While a related DA-cycloadduct **17** [$\text{R} = \text{allyl}$, only 74% *ee*] gave improved yield for the olefination, and while hydrolysis to alkene **19** was fast, the elimination of resulting ketone **20** to ($\pm$)-**7** was neither efficient nor clean. Subsequently, we examined the possibility of first pursuing hydrolysis/elimination sequence. However, while treating **10** with HF or HF/TFA quantitatively gave **21**, the elimination was again slow and sluggish, leading to enone (+)-**3** in low yields accompanied with significant decompositions.

Intriguingly, only after we reduced the aldehyde using LAH, the hydrolysis/elimination sequence could be achieved to cleanly give alcohol (–)-**22**. However, subsequent Dess-Martin periodinane [DMP] oxidation and Wittig olefination were again disastrous in an attempt to synthesize (+)-**7**. On the other hand, alcohol (–)-**22** proved to be useful in accessing vinyl epoxy acetal (+)-**8** through epoxy acetal (–)-**23** in an overall of 4 steps [Scheme 5]. LAH-reduction of the epoxide in **8** followed by TES-protection led to vinyl acetal (+)-**24** in 87% overall yield.

At this point, although we have already examined Suzuki-Miyaura coupling of ($\pm$)-**8** with vinyl bromide **25**,¹⁵ it was not very desirable. Thus, we focused on the cross-coupling of vinyl acetal (+)-**24** with **25** [Scheme 6]. Upon closer examination of the reaction mixture, we were disturbed to find significant quantities of the unexpected olefin **27** [*E/Z* unassigned] in addition to the desired Suzuki-Miyaura cross-product (–)-**26**. It was extremely difficult to separate **27** from (–)-**26**.²⁵

We were certain that this compound was not coming from contamination during the preparation of vinyl bromide **25**.¹⁵ The use of exotic bases such as Cs_2CO_3 , Ti_2CO_3 , Ag_2CO_3 , Ag_2O , or $\text{Ti}(\text{OEt})_2$,²⁴ often critical to the success of these reactions, did not seem to help matters. After trying the PdCl_2dppf and finding it produced a larger amount of by-product **27**, We stuck to

our traditional mode of employing $\text{PdCl}_2(\text{PPh}_3)_2$ for the reaction. While we remain uncertain of the mechanism for this unusual crossed-product, it appears that the addition order mattered. After the 9-BBN hydroboration had occurred, a respective base must be added first to the borane solution before the addition of the palladium/vinyl bromide solution. The most effective catalyst was $\text{Pd}(\text{PPh}_3)_4$, and when it was used at 4.5 mol% along with 2.0 M aq KOH, the formation of **27** was just barely observable by ^1H NMR.

Resolving this quagmire in the Suzuki-Miyaura coupling allowed us to complete an asymmetric synthesis of the ABD-tricycle. As shown in Scheme 7, desilylation followed by DMP oxidation led to acetal enal (+)-**28**, and a careful hydrolysis of acetal (+)-**28** with 1.0 N H_2SO_4 gave the annulation precursor (–)-**29**. Under the *oxa*-[3 + 3] annulation conditions, 10·13 ABD tricycle (+)-**1** was attained in 30% yield²⁷ in an overall 13 steps from diene **9**. The absolute configuration at this point is solely based on Rawal's assignment of related asymmetric Diels-Alder cycloadducts.

We have described here an enantioselective synthesis of the ABD-ring for constructing (–)-phomactin A. The synthetic sequence features Rawal's asymmetric Diels-Alder cycloaddition. The overall length of this new approach is significantly reduced from our previous attempt. Completion of a total synthesis of (–)-phomactin A is in progress.

Experimental Section

Asymmetric Diels-Alder

To a solution of tiglic aldehyde (3.95 mL, 41.0 mmol, 2.0 equiv) in CH_2Cl_2 (20 mL) were added 4 Å molecular sieves (16.5 g), (*R,R*)-Cr(III)-Salen- BF_4 (697.0 mg, 1.02 mmol, 5 mol%) and then diene **9** (7.12 g, 20.5 mmol, 1.0 equiv) and the reaction was stirred at rt for 2 d at rt. The reaction mixture was filtered through a plug of silica gel. The filtrate was concentrated to give a light brown oil. This crude oil was purified via silica gel flash column chromatography (gradient eluent: 5–10% EtOAc in hexanes) to afford the cycloadduct Diels-Alder product **10** (6.90 g) in 78% yield as a yellow oil. **10**: R_f = 0.56 (25% EtOAc in hexanes); $[\alpha]_D^{23} = +48.0$ [c 2.50, CHCl_3]; ^1H NMR (400 MHz CDCl_3) δ : –0.15 (s, 3H), –0.06 (s, 3H), 0.67–0.93 (m, 12H), 1.16 (s, 3H), 1.69–1.77 (m, 1H), 2.11–2.17 (m, 1H), 2.23–2.46 (m, 1H), 3.57 (s, 3H), 4.45 (s, 1H), 4.58–4.61 (m, 2H), 4.84 (s, 1H), 7.08–7.23 (m, 5H), 9.58 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ –4.6, 14.1, 16.6, 18.1, 25.8, 28.4, 35.0, 48.5, 53.0, 53.6, 59.7, 99.5, 126.2, 126.7, 128.3, 139.8, 154.8, 158.0, 205.9; IR (neat) cm^{-1} 2956w, 2931w, 2859w, 1721w, 1692w, 1670w, 1451w, 1393m, 1373m, 1219w, 1201w, 1169m, 835w, 780m; mass spectrum (APCI): m/e (%relative intensity) 267 (13) ($\text{M}+1$)⁺, 432 (100).

LAH Reduction and HF-Hydrolysis

To a solution of the Diels-Alder cycloadduct **10** (6.89 g, 16.0 mmol) in 160 mL of Et_2O at 0 °C was added LAH (1.21 g, 32.0 mmol) portion wise. The reaction was then warmed to rt and stirred overnight. The reaction was cooled to 0 °C, and H_2O (1.21 mL), 10% aq NaOH (1.21 mL) and H_2O (3.63 mL) were added slowly in that order. The mixture was stirred for 1–2 h, and then the white precipitate was formed. The white solid was removed by filtration. The filtrate was concentrated under reduced pressure to give a pale yellow oil.

The above crude oil was taken up in CH_3CN (32 mL) and to this solution was added a HF solution (1.10 mL, 48%, 29.0 M, 32.0 mmol) and the reaction was stirred at rt overnight. The reaction solution was neutralized by addition of aq Na_2CO_3 until the CO_2 bubbles stopped forming. The solid (mostly NaF) was removed by filtration and the filtrate was concentrated *in vacuo*. The crude oil was purified via silica gel flash column chromatography eluting with 10% EtOAc in hexanes to give alcohol (–)-**22** (2.26 g), as a pale yellow oil, in 91% for two steps from the Diels-Alder cycloadduct **10**. Upon sitting, colorless crystals can be formed from

crystallization. (–)-**22**: R_f = 0.19 (40% EtOAc in hexanes); $[\alpha]_D^{23}$ = – 18.0 [*c* 2.50, CHCl₃]; ¹H NMR (500 MHz, CDCl₃) δ 0.97 (s, 3H), 0.98 (d, 3H, *J* = 7.0 Hz), 1.73 (brs, 1H), 2.29 (dd, 1H, *J* = 13.5, 17.0 Hz), 2.36–2.44 (m, 2H), 3.59 (d, 1H, *J* = 11.0 Hz), 3.62 (d, 1H, *J* = 11.0 Hz), 6.01 (d, 1H, *J* = 10.0 Hz), 6.82 (d, 1H, *J* = 10.0 Hz); ¹³C NMR (500 MHz, CDCl₃) δ 15.2, 15.5, 31.8, 41.6, 41.8, 68.1, 128.7, 158.1, 200.1; IR (neat) cm^{–1} 3448s, 2965m, 1662s; mass spectrum (APCI): *m/e* (%relative intensity) 155 (100) (M+1)⁺.

Naproxen Ester Formation for Analyzing Isomeric Ratios

To a solution of give alcohol (–)-**22** (10.0 mg, 0.067 mmol) in CH₂Cl₂ (2 mL) were added (*S*)-naproxen (15.0 mg, 0.067 mmol), DMAP (0.080 mg, 0.0067 mmol), and DCC (14.0 mg, 0.067 mmol). The resulting mixture was stirred for at rt for 18 h. The reaction mixture was simply filtered through a CeliteTM plug and the clear filtrate was concentrated *in vacuo* to give the crude ester **11** as a solid that was subjected to crude NMR analysis for the assessment of diastereomeric ratios. **11**: R_f = 0.62 (40% EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ 0.80 (d, 3H, *J* = 6.6 Hz), 0.91 (s, 3H), 1.54–1.61 (m, 1H), 1.57 (d, 3H, *J* = 6.8 Hz), 1.66–1.71 (m, 1H), 1.88–1.96 (m, 1H), 1.99–2.17 (m, 1H), 2.17 (d, 2H, *J* = 9.2 Hz), 3.91 (s, 3H), 4.03 (d, 2H, *J* = 3.6 Hz), 5.85 (d, 1H, *J* = 10.4 Hz), 6.59 (d, 1H, *J* = 10.4 Hz), 7.10–7.15 (m, 2H), 7.35 (dd, 1H, *J* = 1.6, 8.0 Hz), 7.63–7.68 (m, 3H).

The Oxa-[3 + 3] Annulation: Asymmetric Synthesis of ABD-Ring (+)-1

To a solution of enal (–)-**29** (107.0 mg, 0.35 mmol) in anhyd EtOAc (15 mL - distilled from CaH₂) was added anhyd piperidine (42.0 μL, 0.422 mmol, 1.2 equiv – distilled from and stored with CaH₂) at –10 °C. The solution was stirred to –10°C for 5 min, and then, acetic anhydride (200.0 μL, 2.11 mmol, 6.0 equiv) was added carefully dropwise. The resulting mixture was stirred at rt for 3–4 h before it was washed with equal volume of 1.0 *N* aq NaOH. The organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified using silica gel flash column chromatography (gradient eluent: 0–25% EtOAc in hexanes) to give the desired ABD-tricycle (+)-**1** (32.0 mg) in 30% yield along with byproduct **30a/b** (27.0 mg) in 25% yield. (+)-**1**: R_f = 0.41 (10% EtOAc/hexanes); $[\alpha]_D^{23}$ = + 95 [*c* 0.64, CHCl₃]; ¹H NMR (500 MHz, CDCl₃) δ 6.45 (d, 1H, *J* = 10.5 Hz), 5.15 (brd, 1H, *J* = 10.5 Hz), 4.99 (d, 1H, *J* = 10.5 Hz), 2.87 (dd, 1H, *J* = 6.5, 20.0 Hz), 2.29–2.40 (m, 2H), 2.12 (m, 1H), 2.10 (d, 1H, *J* = 19.5 Hz), 2.06 (ddd, 1H, *J* = 1.5, 7.5, 14.5 Hz), 1.94 (dt, 1H, *J* = 3.5, 14.0 Hz), 1.94 (ddd, 1H, *J* = 2.0, 4.0, 14.5 Hz), 1.89 (ddd, 1H, *J* = 3.5, 12.5, 15.0 Hz), 1.80 (td, 1H, *J* = 3.5, 14.5 Hz), 1.70 (ddd, 1H, *J* = 3.0, 6.0, 15.0 Hz), 1.47 (s, 3H), 1.38 (brm, 3H), 1.07 (s, 3H), 1.02 (d, 3H, *J* = 7.5 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 198.6, 169.1, 134.6, 125.3, 119.8, 118.0, 116.0, 82.9, 47.1, 46.1, 39.5, 37.0, 35.7, 34.5, 31.3, 25.2, 24.6, 20.0, 16.1; IR (neat) cm^{–1} 2976m, 2929m, 2901m, 2835w, 1640vs, 1607s, 1449m, 1416s; mass spectrum (ESI) *m/e* (% relative intensity) 309.2 (M + Na)⁺ (100), 197.0 (13); *m/e* calcd for C₁₉H₂₆O₂Na (M + Na)⁺ 309.1830, found 309.1818 [δ = 3.89ppm].

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Authors thank NIH [NS38049] for funding, and KPC thanks ACS-ORG for a fellowship sponsored by Schering-Plough. We thank Professor Viresh H. Rawal and Dr. Yong Huang [The University of Chicago] for invaluable discussions.

References

1. Sugano M, Sato A, Iijima Y, Oshima T, Furuya K, Kuwano H, Hata T, Hanzawa H. *J Am Chem Soc* 1991;113:5463.
2. (a) Sugano M, Sato A, Saito K, Takaishi S, Matsushita Y, Iijima Y. *J Med Chem* 1996;39:528. (b) Xhu X, Muñoz NM, Kim KP, Sano H, Cho W, Leff AR. *J Immunol* 1999;163:342. (c) Sugano M, Sato A, Iijima Y, Furuya K, Haruyama H, Yoda K, Hata T. *J Org Chem* 1994;59:56. (d) Sugano M, Sato A, Iijima Y, Oshima T, Furuya K, Hata T, Kuwano H. *J Antibiot* 1995;48:1188. [PubMed: 7490234]
3. Also see: Zhu X, Lambertino AT, Houghton TJ, McGilvra JD, Xu C, Rawal VH, Leff AR. *Life Sciences* 2003;73:3005. [PubMed: 14519449]
4. For reviews on synthetic efforts toward phomactins, see: (a) Cole KP, Hsung RP. *ChemTracts* 2003;16:81. (b) Goldring WPD, Pattenden G. *Acc Chem Res* 2006;39:354. [PubMed: 16700534]
5. For synthetic approaches, see: (a) Foote KM, Hayes CJ, Pattenden G. *Tetrahedron Lett* 1996;37:27. (b) Chen D, Wang J, Totah NI. *J Org Chem* 1999;64:177. (c) Seth PP, Totah NI. *J Org Chem* 1999;64:875. (d) Seth PP, Totah NI. *Org Lett* 2000;2:250. (e) Kallan NC, Halcomb RL. *Org Lett* 2000;2:268. (f) Chemler SR, Danishefsky SJ. *Org Lett* 2000;2:269. [PubMed: 10814299] (g) Seth PP, Chen D, Wang J, Gao X, Totah NI. *Org Lett* 2000;56:10185. (h) Foote K, John M, Pattenden G. *Synlett* 2001:36. (i) Mi B, Maleczka R. *Org Lett* 2001;3:149. [PubMed: 11430021] (j) Chemler SR, Iserloh U, Danishefsky SJ. *Org Lett* 2001;3:294. (k) Houghton T, Choi S, Rawal VH. *Org Lett* 2001;3:361. [PubMed: 11428014] (l) Mohr PJ, Halcomb RL. *Org Lett* 2002;4:241. [PubMed: 11796060] (m) Balnaves AS, McGowan G, Shapland PDP, Thomas EJ. *Tetrahedron Lett* 2003;44:271. (n) Cheing JWC, Goldring WPD, Pattenden G. *Chem Commun* 2003:2788. (o) Ryu K, Cho YS, Jung SI, Cho CG. *Org Lett* 2006;8:334. (p) Huang J, Wang H, Wu C, Wulff WD. *Org Lett* 2007;9:279. [PubMed: 17217284] (q) Seth PP, Chen D, Wang J, Gao X, Totah NI. *Tetrahedron Lett* 2007;48:4605. [PubMed: 18575571]
6. For total synthesis of (+)-phomactin D, see: Miyaoka H, Saka Y, Miura S, Yamada Y. *Tetrahedron Lett* 1996;37:7107.
7. For total synthesis of (±)-phomactin A, see: (a) Goldring WPD, Pattenden G. *Chem Commun* 2002:173. (b) Diaper CM, Goldring WPD, Pattenden G. *Org Biomol Chem* 2003;1:394. (c) Foote KM, Hayes CJ, John MP, Pattenden G. *Org Biomol Chem* 2003;1:3917. [PubMed: 14664383]
8. For total synthesis of (+)-phomactin A, see: Mohr PJ, Halcomb RL. *J Am Chem Soc* 2003;125:1712. [PubMed: 12580592]
9. For total synthesis of (±)-phomactin B2, see: Huang J, Wu C, Wulff WD. *J Am Chem Soc* 2007;129:13366. [PubMed: 17929921]
10. Cole KP, Hsung RP. *Org Lett* 2003;5:4843. [PubMed: 14653688]
11. Cole KP, Hsung RP. *Chem Commun* 2005:5784.
12. For reviews, see: (a) Harrity JPA, Provoost O. *Org Biomol Chem* 2005;3:134. (b) Hsung RP, Kurdyumov AV, Sydorenko N. *Eur J Org Chem* 2005;1:2. (c) Cole, KP.; Hsung, RP. *Strategies and Tactics in Organic Synthesis*. Harmata, M., editor. Vol. 14. Pergamon Press; Oxford: 2004. p. 41
13. For our methodological developments, see: (a) Kurdyumov AV, Lin N, Hsung RP, Gullickson GC, Cole KP, Sydorenko N, Swidorski JJ. *Org Lett* 2006;8:19. [PubMed: 16381557] (b) Shen HC, Wang J, Cole KP, McLaughlin MJ, Morgan CD, Douglas CJ, Hsung RP, Coverdale HA, Gerasyuto AI, Hahn JM, Liu J, Wei LL, Sklenicka HM, Zehnder LR, Zifcsak CA. *J Org Chem* 2003;68:172. (c) Hsung RP, Wei LL, Sklenicka HM, Douglas CJ, McLaughlin MJ, Mulder JA, Yao L. *Org Lett* 1999;1:50. For applications in natural product syntheses, see: (d) Kurdyumov AV, Hsung RP. *J Am Chem Soc* 2006;128:627. (e) Kurdyumov AV, Hsung RP, Ihlen K, Wang J. *Org Lett* 2003;5:393. (f) Hsung RP, Cole KP, Zehnder LR, Wang J, Wei LL, Yang XF, Coverdale HA. *Tetrahedron* 2003;59:311.
14. For recent studies on related annulations, see: (a) Brioché JCR, Goodenough KM, Whatrup DJ, Harrity JPA. *J Org Chem* 2008;73:194. (b) Yavari I, Sabbaghan M, Hossaini Z. *Synlett* 2008:115. (c) Hubert C, Moreau J, Batany J, Duboc A, Hurvois JP, Renaud JL. *Adv Syn Cat* 2008;350:4. (d) Zhu M, Wei Q, Gong L. *Adv Synth Catal* 2008;350:128. (e) Zhong W, Lin F, Chen R, Su W. *Synthesis* 2008:2561. (f) Brioché JCR, Goodenough KM, Whatrup DJ, Harrity JPA. *Org Lett* 2007;9:3491. [PubMed: 17685530] (g) Lee YR, Xia L. *Synthesis* 2007:324. (h) Epstein OL, Rovis T. *J Am Chem Soc* 2006;128:1648. [PubMed: 16448138] (i) Mondal M, Puranik VG, Argade NP. *J Org Chem*

2006;71:4992. [PubMed: 16776532] (j) Lee YR, Lee WK, Noh SK, Lyoo WS. *Synthesis* 2006;85. (k) Lee YR, Kim DH. *Synthesis* 2006;603. (l) Sheibani H, Mosslemin MH, Behzadi S, Islami MR, Saidi K. *Synthesis* 2006;43. (m) Grecian S, Wroblewski AD, Aube J. *Org Lett* 2005;7:316. (n) Sagar R, Singh P, Kumar R, Maulik PR, Shaw AK. *Carbohydr Res* 2005;340:128. (o) Itoh K, Hasegawa M, Tanaka J, Kanemasa S. *Org Lett* 2005;7:97. (p) Pettigrew JD, Cadieux JA, So SSS, Wilson PD. *Org Lett* 2005;7:46. (q) Lee YR, Wang X. *Bull Korean Chem Soc* 2005;26:1933. (r) Olson BS, Trauner DJ. *Synlett* 2005:70. (s) Sunazuka T, Handa M, Nagai K, Shirahata T, Harigaya Y, Otoguro K, Kuwajima I, Omura S. *Tetrahedron* 2004;60:784. (t) Hu H, Harrison TJ, Wilson PD. *J Org Chem* 2004;69:3782. [PubMed: 15153009]

15. See supporting information for procedures and characterizations of new compounds.
16. (a) Kozmin SA, Rawal VH. *J Org Chem* 1997;62:525. (b) Kozmin SA, Rawal VH. *J Am Chem Soc* 1997;119:7165.
17. (a) Kozmin SA, Janey JM, Rawal VH. *J Org Chem* 1999;64:303. (b) Kozmin SA, Rawal VH. *J Am Chem Soc* 1999;121:956. (c) Kozmin SA, He S, Rawal VH. *Org Synth* 2000;78:15, 160.
18. Kozmin SA, Green MT, Rawal VH. *J Org Chem* 1999;64:8045.
19. (a) Huang Y, Iwama T, Rawal VH. *J Am Chem Soc* 2000;122:784. (b) Huang, Yong. PhD thesis. (c) Huang Y, Iwama T, Rawal VH. *Org Lett* 2002;4:116. Also see: (d) Kozmin SA, Iwama T, Huang Y, Rawal VH. *J Am Chem Soc* 2002;124:462. [PubMed: 11792217] (e) Kozmin SA, Rawal VH. *J Am Chem Soc* 1998;124:4628. [PubMed: 11971711]
20. Huang Y, Iwama T, Rawal VH. *J Am Chem Soc* 2002;124:5950. [PubMed: 12022822]
21. Hu QY, Zhou G, Corey EJ. *J Am Chem Soc* 2004;126:13708. [PubMed: 15493929]
22. For some recent applications and studies involving Rawal's diene, see: (a) Padwa A, Bur SK, Zhang H. *J Org Chem* 2005;70:683. (b) Tiefenbacher K, Mulzer J. *Angew Chem Int Ed* 2008;47:619. (c) Hayashida J, Rawal VH. *Angew Chem Int Ed* 2008;47:437. (d) Gordillo R, Budding T, Anderson CD, Houk KN. *Org Lett* 2007;9:50. (e) Kawęcki R. *Tetrahedron: Asymmetry* 2006;17:1420.
23. The use of Danishefsky's diene and Corey's oxazaborolidine catalyst 12 only returned the related 1,4-addition product i and 1,2-addition product ii.

24. (a) Jacobsen EN. *Acc Chem Res* 2000;33:42. (b) Tokunaga MJ, Larrow F, Kakiuchi F, Jacobsen EN. *Science* 1997;277:93. For application of Cr(III)-salen catalysts in enantioselective hetero-Diels-Alder reactions: (c) Schaus S, Brånalt J, Jacobsen EN. *J Org Chem* 1998;63:403.
25. Only after deprotection of the TES ether, some chromatographic separation was observed which allowed us to attain a sufficiently pure sample to characterize the side product 27.
26. Frank SA, Chen H, Kunz RK, Schnaderbeck MJ, Roush WR. *Org Lett* 2000;2:2691. [PubMed: 10990429]
27. Also isolated was 25% yield of the two wrong tricycles iiia and iiib as an inseparable 4:1 atropisomeric mixture [see reference 11].

Scheme 1.
A synthetic approach to phomactin A.

a. $\text{Ph}_3\text{PBrCH}_3$, $n\text{-BuLi}$, THF, 0 °C to rt. **b.** 4.0 M HF in THF, 0 °C to rt.
c. K_2CO_3 , H_2O_2 , MeOH, 0 °C to rt. **d.** $\text{HOCH}_2\text{CH}_2\text{OH}$, $p\text{-TsOH}$, PhH, 80 °C.

Scheme 2.
 Danishefsky's diene versus Rawal's diene.

catalyst 12:	-	-	
13:	36%	[85% ee]	
14:	-	-	
15:	78%	[82-90% ee]	

catalysts:

R*CO₂H =

Scheme 3.
Rawal's asymmetric Diels-Alder cycloaddition.

Scheme 4.
Struggles in accessing enone (+)-7

Scheme 5.

A suitable path to vinyl epoxy acetal (+)-8.

**BUT: If adding aq KOH,
 K₃PO₄, or Cs₂CO₃
 to the borane first,
 and then add vinyl bromide
 and 4.5 mol% Pd(PPh₃)₄**

ratio:	3	1
yield	undetermined	
→		
ratio:	20	1
yield	92%	

Scheme 6.
 A strange Suzuki-Miyaura coupling.

Scheme 7.
Synthesis of ABD-ring (+)-1 for (–)-phomactin A.